WO2000021963A1 - Il-8 receptor antagonists - Google Patents
Il-8 receptor antagonists Download PDFInfo
- Publication number
- WO2000021963A1 WO2000021963A1 PCT/US1999/023776 US9923776W WO0021963A1 WO 2000021963 A1 WO2000021963 A1 WO 2000021963A1 US 9923776 W US9923776 W US 9923776W WO 0021963 A1 WO0021963 A1 WO 0021963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- alkyl
- alkenyl
- heteroaryl
- aryl
- Prior art date
Links
- RXLSFJMOQBANOE-UHFFFAOYSA-N CC(C=C1C2)(C=NC(N)=C1NS2(=O)=O)N Chemical compound CC(C=C1C2)(C=NC(N)=C1NS2(=O)=O)N RXLSFJMOQBANOE-UHFFFAOYSA-N 0.000 description 1
- QHAFTYLQBDXWHM-UHFFFAOYSA-N CC(C=C1C2)(N)N=CC(N)=C1NS2(=O)=O Chemical compound CC(C=C1C2)(N)N=CC(N)=C1NS2(=O)=O QHAFTYLQBDXWHM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to novel cyclic pyridyl substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2, and ENA-78 mediated diseases.
- Interleukin-8 Interleukin-8
- NAP-1 neutrophil attractant/activation protein- 1
- MDNCF monocyte derived neutrophil chemotactic factor
- NAF neutrophil activating factor
- T-cell lymphocyte chemotactic factor T-cell lymphocyte chemotactic factor.
- Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells. It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-la, IL-lb or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP.
- GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 also belong to the chemokine a family. Like IL-8 these chemokines have also been referred to by different names. For instance GRO ⁇ , ⁇ , ⁇ have been referred to as MGSAa, b and g respectively
- chemokines of the ⁇ -family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor.
- IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2, and ENA-78 stimulate a number of functions in vitro. They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GRO ⁇ have demonstrated T-lymphocytes, and basophilic chemotactic activity.
- IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO- ⁇ and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils.
- IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration.
- GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 promote the accumulation and activation of neutrophils
- these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al., FEBS Lett. 307, 97 (1992); Miller et al., Crit. Rev. Immunol. 12, 17 (1992); Oppenheim et al., Annu. Rev. Immunol. 9, 617 (1991); Seitz et al., J. Clin. Invest. 87, 463 (1991); Miller et al., Am. Rev. Respir. Pis.
- ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis. Strieter et al., Science 258, 1798 (1992).
- IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the B -receptor.
- the development of non-peptide small molecule antagonists for members of this receptor family has precedent.
- the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents.
- IL-8Ra which binds only IL-8 with high affinity
- IL-8Rb which has high affinity for IL-8 as well as for GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2.
- IL-8Ra which binds only IL-8 with high affinity
- IL-8Rb which has high affinity for IL-8 as well as for GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2.
- This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I), (II), or (III) or a pharmaceutically acceptable salt thereof.
- the chemokine is IL-8.
- This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III).
- the present invention also provides for the novel compounds of Formula (I), (II), or (III) and pharmaceutical compositions comprising a compound of Formula (I), (II, or (III) and a pharmaceutical carrier or diluent.
- R is -NH -C(X)-NH- (CR 13 R 14 ) V - Z;
- X is oxygen or sulfur
- Z is W, HET, ( ⁇ Y ⁇ )n ⁇ , an optionally substituted C i . ⁇ Q alkyl, an optionally substituted C2-10 alkenyl, or an optionally substituted C2-I0 alkynyl;
- Rl is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Cj-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CRgRg)q S(O) t R_ ⁇ , hydroxy, hydroxy Ci-4alkyl, aryl, aryl C ⁇ -4 alkyl, aryloxy, aryl Ci-4 alkyloxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic Ci-4alkyl, heteroaryl Ci-4 alkyloxy, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CRgRg)qNR4R5, C2-10 alkenyl C(O)NR 4 R5, (CRgR 8 )q C(O)NR 4 R5, (CRgRg)q C(O)NR
- aryl, heteroaryl, and heterocyclic containing moieties may all be optionally substituted;
- m is an integer having a value of 1 to 3;
- n is an integer having a value of 1 to 3;
- p is an integer having a value of 1 to 3;
- q is 0, or an integer having a value of 1 to 10;
- s is an integer having a value of 1 to 3;
- t is 0, or an integer having a value of 1 or 2;
- v is 0, or an integer having a value of 1 to 4;
- HET is an optionally substituted heteroaryl;
- R4 and R5 are independently hydrogen, optionally substituted Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci-4alkyl, heterocyclic, heterocyclic Ci-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S;
- Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted -io alkoxy, (CRgRg)q S(O) t R4, hydroxy, hydroxyCi-4alkyl, aryl, aryl -4 alkyl, aryloxy, arylCj-4 alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl Cj-4 alkyloxy, heterocyclic, heterocyclic Ci-4alkyl, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CRgRg)q NR4R5, C2-10 alkenyl C(O)NR 4 R5, (CRgRg)q C(O)NR 4 R 5 , (CRgRg)q C(O)
- Rg is hydrogen or C 1-4 alkyl
- RlO is C 1-10 alkyl C(O)2R8;
- Rl 1 is hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi_4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl;
- Rl2 is hydrogen, Ci-io alkyl, optionally substituted aryl or optionally substituted arylalkyl;
- Rl 3 and R14 are independently hydrogen, optionally substituted Ci-4 alkyl, or one of R ⁇ 3 and R14 may be optionally substituted aryl;
- Rl7 is Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl;
- R g is hydrogen, optionally substituted C ⁇ _ ⁇ o alky
- the E containing ring is optionally selected from
- the compounds of Formula (I), (II) and (III) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 ⁇ and ⁇ receptors.
- Chemokine mediated diseases for treatment, therapeutic ally or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section.
- Ri is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Ci-io alkyl, such as CF 3 ; Ci-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl; C2-10 alkenyl; Ci-io alkoxy, such as methoxy, or ethoxy; halosubstituted Ci-io alkoxy, such as trifluoromethoxy; (CRgRg)q S(O) t R4, wherein t is 0, 1 or 2; hydroxy; hydroxy C ⁇ _4alkyl, such as methanol or ethanol; aryl, such as phenyl or naphthyl; aryl Ci-4 alkyl, such as benzyl; aryloxy, such as phenoxy; aryl Ci-4 alkyloxy, such as benzyloxy; heteroaryl; heteroarylalkyl; heteroaryl Ci-4
- the term "the aryl, heteroaryl, and heterocyclic containing moieties” refers to both the ring and the alkyl, or if included, the alkenyl rings, such as aryl, arylalkyl, and aryl alkenyl rings.
- the term “moieties” and “rings” may be interchangeably used throughout.
- R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci-4alkyl, heterocyclic, heterocyclicC 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O N/S.
- Rg is independently hydrogen or C 1-4 alkyl.
- q is 0 or an integer having a value of 1 to 10.
- Rio is C ⁇ _ ⁇ o alkyl C(O)2R 8 , such as CH2C(O)2H or
- Ri i is hydrogen, Ci-4 alkyl, aryl, aryl Ci-4 alkyl, heteroaryl, heteroaryl Cj-4alkyl, heterocyclic, or heterocyclic C -4alkyl.
- R12 is hydrogen, C _IQ alkyl, optionally substituted aryl or optionally substituted arylalkyl.
- R ⁇ 3 and R14 are independently hydrogen, or an optionally substituted C _4 alkyl which may be straight or branched as defined herein, or one of R ⁇ 3 and R 14 are an optionally substituted aryl.
- v is 0, or an integer having a value of 1 to 4.
- R ⁇ 3 or R14 are an optionally substituted alkyl
- the alkyl moiety may be substituted one to three times independently by halogen; halosubstituted Ci-4 alkyl such as trifluoromethyl; hydroxy; hydroxy Cj-4alkyl; Cj-4 alkoxy; such as methoxy, or ethoxy; halosubstituted Ci-io alkoxy; S(O)tR4; aryl; NR4R5; NHC(O)R4; C(O)NR4Rs; or C(O)OR 8 .
- R17 is C ⁇ _4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC ⁇ _4alkyl, heterocyclic, or heterocyclicC i-4alkyl, wherein all of the aryl, heteroaryl and heterocyclic containing moieties may all be optionally substituted.
- Y is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Ci-io alkyl; Cj-io alkyl; C2-10 alkenyl; Ci-io alkoxy; halosubstituted Ci-io alkoxy; azide; (CR R 8 )q S(O) t R4; hydroxy; hydroxyCi-4alkyl; aryl; aryl Ci-4 alkyl; aryloxy; arylCi-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl Ci-4 alkyloxy; heterocyclic, heterocyclic Ci-4alkyl; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl; heterocyclic C2-10 alkenyl; (CR Rg)q
- NR4R5; C2-10 alkenyl C(O)NR4R5; (CRgRg)q C(O)NR 4 R 5 ; (CR 8 Rg)qC(O)NR 4 Rl0; S(O) 3 H; S(O) 3 R 8 ; (CR 8 R 8 )q C(O)Rn; C 2 -10 alkenyl C(O)Rn; C2-10 alkenyl C(O)ORn ; (CR 8 R 8 )q C(O)OR ⁇ 2 ; (CR 8 R 8 )q OC(O) Rn; (CR 8 R )qC(NR4)NR4R 5 ; (CRgRg)q NR 4 C(NR 5 )R ⁇ ⁇ ; (CRgR 8 )q NR4C(O)Ri i; (CRgRg)q NHS(O) 2 R a ; or (CR 8 R 8 )q S(O)2NR 4 R5; or two Y moieties together may
- s is an integer having a value of 1 to 3.
- s is preferably 1.
- Y forms an additional unsaturated ring, it is preferably 6 membered resulting in a naphthylene ring system.
- These ring systems may be substituted 1 to 3 times by other Y moieties as defined above.
- R a is NR4R5, alkyl, aryl C ⁇ _4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C ⁇ _4 alkyl, heteroarylC2-4 alkenyl, heterocyclic, or heterocyclicC 1.4 alkyl, wherein all of the aryl, heteroaryl and heterocyclic containing rings may all be optionally substituted.
- Y is preferably a halogen, C ⁇ _4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or arylalkoxy, methylene dioxy, NR4R5, thio Ci-4alkyl, thioaryl, halosubstituted alkoxy, optionally substituted Ci-4 alkyl, or hydroxy alkyl.
- Y is more preferably mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are mono or di-substituted in the 2'- position or 2'-, 3 '-position.
- n is preferably one. While both R and Y can both be hydrogen, it is preferred that at least one of the rings be substituted, preferably both rings are substituted.
- R is -NH -C(X)-NH- (CR 3 R 4) v - Z.
- Z is W, HET, ( ⁇ ) n , an optionally substituted C io alkyl, an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl.
- p is an integer having a value of 1 to 3.
- X is oxygen or sulfur, preferably oxygen.
- Z is a heteroaryl (HET) ring
- HET heteroaryl
- the ring containing the heteroatom does not need to be directly attached to the urea moiety through the (Rl 3 Rj4) v linkage. Any of the ring(s) in these systems may be optionally substituted as defined herein.
- the HET moiety is a pyridyl, which may be 2-, 3- or 4-pyridyl. If the ring is a multi system ring it is preferably benzimidazole, dibenzothiophene, or an indole ring.
- rings of interest include, but are not limited to thiophene, furan, pyrimidine, pyrrole, pyrazole, quinoline, isoquinoline, quinazolinyl, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
- the HET ring may be optionally substituted independently one to five, preferably 1 to 3 times by Y as defined above.
- the substitutions may be in any of the ring(s) of the HET system, such as in a benzimidazole ring.
- R15 and R are independently hydrogen, or an optionally substituted Ci-4 alkyl as defined above for R ⁇ 3 and R14.
- W is , or
- the E containing ring is optionally selected from ent of the ring.
- the E ring denoted by its point of attachment through the asterix (*) may optionally be present. If it is not present the ring is a phenyl moiety which is substituted by the Y terms as shown.
- the E ring may be substituted by the (Y)n moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated ring(s).
- Y in the W term may be substituted in any of the 5 ring positions of the phenyl moiety (when E is absent), Y is preferably mono-substituted in the 2 - position or 3'- position, with the 4'- preferably being unsubstituted. If the phenyl ring is disubstituted, substituents are preferably in the 2' or 3' position of a monocyclic ring. While both Ri and Y can both be hydrogen, it is preferred that at least one of the rings be substituted, preferably both rings are substituted.
- R ⁇ 8 is hydrogen, optionally substituted Ci-io alkyl, Ci-io alkoxy, halosubstituted C ⁇ _ ⁇ o alkoxy, hydroxy, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-C ⁇ _4alkyl, heteroarylC2-4 alkenyl, heterocyclic, or heterocyclicC j .4 alkyl, wherein the aryl, heteroaryl and heterocyclic containing moieties may all be optionally substituted.
- R ⁇ 8 is hydrogen or alkyl, more preferably hydrogen.
- halogen such as fluorine, chlorine, bromine or iodine
- hydroxy hydroxy substituted Ci-ioalkyl
- Ci-io alkoxy such as methoxy or ethoxy
- S(O)m' Ci-io alkyl wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl
- amino, mono & di-substituted alkyl amino such as in the NR4R5 group; NHC(O)R4; C(O)NR R 5 ; C(O)OH; S(O) 2 NR4R5; NHS(O) 2 R20, Cl-10 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl
- halosubstituted Ci-io alkyl such CF 3 ;
- Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
- pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety.
- Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
- halo all halogens, that is chloro, fluoro, bromo and iodo.
- cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl and the like.
- aryl - phenyl and naphthyl; • “heteroaryl” (on its own or in any combination, such as “heteroaryloxy", or “heteroaryl alkyl”) - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.
- heterocyclic (on its own or in any combination, such as “heterocyclicalkyl”) - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
- arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Ci-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.
- sulfinyl - the oxide S (O) of the corresponding sulfide
- thio refers to the sulfide
- sulfonyl refers to the fully oxidized S(O)2 moiety.
- Ri moieties may together form a 5 or 6 membered saturated or unsaturated ring
- an aromatic ring system such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a C6 cycloalkenyl, i.e, hexene, or a C5 cycloalkenyl moiety, such as cyclopentene.
- Compounds of Formula (II) are useful in a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
- the chemokine is IL-8.
- This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (II).
- the present invention also provides a novel pharmaceutical composition
- a novel pharmaceutical composition comprising a compound of Formula (II) and a pharmaceutical carrier or diluent.
- R is -NH -C(X)-NH- (CR ⁇ 3 R ⁇ 4 ) v - Z;
- X is oxygen or sulfur
- Z is W, HET, ' ) n , an optionally substituted C -io alkyl, an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl;
- Rj is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-10 alkoxy, halosubstituted Ci-io alkoxy, (CR 8 R 8 )q S(O)tF 4, hydroxy, hydroxy Ci-4alkyl, aryl, aryl C ⁇ _4 alkyl, aryloxy, aryl Cj-4 alkyloxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic Ci_4alkyl, heteroaryl Ci-4 alkyloxy, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CR 8 R 8 )qNR4R5, C2-10 alkenyl C(O)NR R5, (CR 8 R 8 )q C(O)NR4R5, (CR 8 R 8 )q C(O)NR 4
- R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci-4alkyl, heterocyclic, heterocyclic Ci-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S; Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR R 8 )q S(O) t R4, hydroxy, hydroxyCi-4alkyl, aryl, aryl Cj-4 alkyl, aryloxy, arylCi-4 alkyloxy, heteroaryl, heteroaryl
- R 8 is hydrogen or Ci-4 alkyl;
- RlO is C i-io alkyl C(O) 2 R 8 ;
- Rl l is hydrogen, Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCj-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC i _4alkyl ;
- Rl2 is hydrogen, Ci-io alkyl, optionally substituted aryl or optionally substituted arylalkyl;
- Rl 3 and R14 are independently hydrogen, optionally substituted Ci-4 alkyl, or one of R ⁇ and R14 may be optionally substituted aryl;
- R 17 is C 1-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 _4alkyl;
- Rl is hydrogen, optionally substituted Ci-io alkyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, hydroxy, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-
- R a is NR4R5, alkyl, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl- C ⁇ _4 alkyl, heteroarylC2_4 alkenyl, heterocyclic, or heterocyclicC 1.4 alkyl; and wherein the aryl, heteroaryl and heterocyclic containing moieties may all be optionally substituted;
- the E containing ring is optionally selected from
- Illustrative compounds of Formula (II) include: N-(l,3-dihydro-2,2-dioxidoisothiazolo[4,3-b]pyridin-7-yl)-N-(2- bromophenyl)urea;
- Compounds of Formula (III) are useful in a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
- the chemokine is IL-8.
- This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (III).
- the present invention also provides a novel pharmaceutical composition
- a novel pharmaceutical composition comprising a compound of Formula (III) and a pharmaceutical carrier or diluent.
- R is - ⁇ H -C(X)- ⁇ H- (CR ⁇ 3 R 14 ) v - Z;
- X is oxygen or sulfur
- Z is W, HET, ( ⁇ ) n , an optionally substituted C 10 alkyl, an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl;
- Rl is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR R 8 )q S(O)tR4, hydroxy, hydroxy C ⁇ _4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, aryl Ci-4 alkyloxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic Ci-4alkyl, heteroaryl C ⁇ _4 alkyloxy, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CR R 8 )qNR4R5, C2-10 alkenyl C(O)NR 4 R5, (CR 8 R 8 )q C(O)NR4R5, (CR 8 R 8 )q C(O)NR
- HET is an optionally substituted heteroaryl
- R4 and R5 are independently hydrogen, optionally substituted C ⁇ -A alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C ⁇ _4alkyl, heterocyclic, heterocyclic Ci_4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O N/S;
- Y is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, C ⁇ io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CR 8 Rg)q S(O)tR4, hydroxy, hydroxyC i-4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, arylCj-4 alkyloxy,
- RlO is C 1-10 alkyl C(O)2R 8 ;
- Rl 1 is hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl ;
- Rl2 is hydrogen, Ci-io alkyl, optionally substituted aryl or optionally substituted arylalkyl;
- Rl 3 and R 14 are independently hydrogen, optionally substituted Cj-4 alkyl, or one of R ⁇ 3 and R14 may be optionally substituted aryl;
- R17 is Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Cj-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ⁇ _4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 _4alkyl ;
- Rjg is hydrogen, optionally substituted Ci-io alkyl, Cj-io alkoxy, halosubstituted Ci- io alkoxy, hydroxy, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl-
- R a is NR4R5, alkyl, arylC ⁇ .4 alkyl, arylC 2-4 alkenyl, heteroaryl, heteroaryl- C ⁇ alkyl, heteroarylC2-4 alkenyl, heterocyclic, or heterocyclicC j .4 alkyl; and wherein the aryl, heteroaryl and heterocyclic containing moieties may all be optionally substituted;
- the E containing ring is optionally selected from
- Ilustrative compounds of Formula (III) include:
- the compounds of Formulas (I), (II) and (III) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below.
- the synthesis provided for in these Schemes is applicable for the producing compounds of Formulas (I), (II) and (III) having a variety of different R, Ri, and Z groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed.
- further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art.
- compound 1 -scheme 1 is then brominated under standard conditions (H2SO4 and Br2).
- compound 2-scheme 1 is then oxidized under standard conditions ( Fuming H2SO4/ 30% H2O2).
- Compound 3-scheme 1 can be treated with standard bromination conditions (NBS), followed by standard sulfamide formation via the thioacetate(sodium thioacetate, DMF), sulfonyl chloride(AcOH/sodium acetate/C ⁇ ), and then sulfamide formation (ammonium hydroxide or ammonia gas) to give compound 4-scheme 1.
- NBS standard bromination conditions
- the aniline 5-scheme 1 may be prepared by cyclization of compound 4-scheme 1, followed by standard reduction condition (Pd/C and H2 or SnCl2, thiol, or zinc in acetic acid).
- the ortho substituted phenyl urea in 6-scheme 1 may be prepared by standard conditions involving the condensation of the commercially available substituted aryl isocyanate (Aldrich Chemical Co., Milwaukee,Wi.) with the corresponding aniline 5-scheme 7 in an aprotic solvent such as (DMF or toluene).
- the bromo substituent on 4-6- scheme-1 can be further eleaborated using palladium catalyzed arylation, Heck reactions or carbonylation. Alternately the bromide can be displaced using nucleophilic conditions such as sodium alkoxides, azide, thiols or cyanide. These functional groups can then be further interconverted using conditions well known in the art.
- the sulfonyl chloride hydrolyses to the sulfonic acid it can be converted back to the sulfonyl chloride using POCl .
- the sulfonyl chloride can then be reacted with ammonium hydroxide or ammonia gas to form the sulfonamide 3-scheme-2.
- the sulfonamide can then be cyclized using potassium carbonate in an aprotic polar solvent such as DMF, DMSO or propionitrile to form the corresponding cyclic sulfonamide.
- the nitro can then be reduced using standard conditions such as Pd/C and H2 or SnCl2, thiol, or zinc in acetic acid to form the amine 4-scheme-2.
- the amine can be coupled with the commericially available isocyanate, 5-scheme-2.
- the desired isocyanates can be made by condensing the amine with triphosgene in the presence of base (such as potassium carbonate) or by reacting the carboxylic acid with diphenyl phosphorazide in the presence of a base (such as triethyl amine).
- base such as potassium carbonate
- the aromatic rings can be further functionalized by halogenation using a halogen in the presence of an acid or lewis acid or a perhalogenated salt such as pyridinium bromide perbromide to form the brominated aromatic. It is recognized that a mixture of isomers may be produced in this reaction.
- the isomers can be separated by chromatography.
- the bromine can then be displaced by a nucleophile such as cupric cyanide or sodium methoxide in a polar aprotic solvent such as DMF or DMSO.
- a nucleophile such as cupric cyanide or sodium methoxide
- a polar aprotic solvent such as DMF or DMSO.
- the bromide can be used for palladium-catalyzed coupling or carbonylation reactions.
- the amine can be converted the chlorine by diazotization with sodium nitrite in aqueous hydrochloric acid followed the addition of copper chloride to form the corresponding aromatic chloride.
- This compound can then be oxidized to form the nitro pyridine n-oxide to form 2-scheme-3.
- the methyl can then be brominated under radical bromination conditions such as NBS.
- the bromide can be converted to the corresponding sulfonamide using the following three step procedure.
- the bromide can be reacted with sodium thioacetate.
- This thioacetate can be converted to the sulfonyl chloride using chlorine gas in aqueous acetic acid. If the sulfonyl chloride hydrolyses to the sulfonic acid it can be converted back to the sulfonyl chloride using POCl 3 .
- the sulfonyl chloride can then be reacted with ammonium hydroxide or ammonia gas to form the sulfonamide 3-scheme-3.
- the sulfonamide can then be cyclized using potassium carbonate in an aprotic polar solvent such as DMF, DMSO or propionitrile to form the corresponding cyclic sulfonamide 3-scheme-3.
- the nitro can then be reduced using standard conditions such as Pd/C and H2 or SnCl2, thiol, or zinc in acetic acid to form the amine 4-scheme-3.
- the amine can be coupled with the commericially available isocyanate.
- the desired isocyanates can be made by condensing the amine with triphosgene in the presence of base (such as potassium carbonate) or by reacting the carboxylic acid with diphenyl phosphorazide in the presence of a base (such as triethyl amine) to form 5-scheme-3.
- base such as potassium carbonate
- diphenyl phosphorazide such as triethyl amine
- All of the aromatic rings can be further functionalized by halogenation using a halogen in the presence of an acid or lewis acid or a perhalogenated salt such as pyridinium bromide perbromide to form the brominated aromatic. It is recognized that a mixture of isomers may be produced in this reaction. The isomers can be separated by chromatography. The bromine can then be displaced by a nucleophile such as cupric cyanide or sodium methoxide in a polar aprotic solvent such as DMF or DMSO. Alternatively the bromide can be used for palladium-catalyzed coupling or carbonylation reactions.
- the nitro pyridine n-oxide l-scheme-4 which was described previously can be alkylated with an allyl group to form 2-scheme-4 in the presence of a base such as potassium carbonate, or sodium hydride to form 2-scheme-4.
- the methylene of the cyclic sulfonamide can then be alkylated by an alkyl halide in the presence of sodium hydride or lithium heaxamethyldisilazine to form 3-scheme -4.
- the methylene can also be functionalized by reaction with an isocyanate or thio isocyanate in the presence of a base to form the corresponding amide or thio amide.
- the methylene can be halogenated using an electrophilic halogen source such as N-fluoro benzene-sulfonimide or N-bromosuccinimide in the presence of a base such as sodium hydride, triethyl amine or sodium heaxamethyl disilazine.
- an electrophilic halogen source such as N-fluoro benzene-sulfonimide or N-bromosuccinimide
- a base such as sodium hydride, triethyl amine or sodium heaxamethyl disilazine.
- This benzylic halide can be displaced by a variety of nucleophiles such as alcohols, thiols, or amines in the presence of a base such as sodium hydride, triethyl amine or sodium heaxamethyl disilazine.
- the allyl can be deprotected using a palladium catalyst in the presence of a reducing agent such as sodium borohydride and the nitro can be reduced by standard conditions such as conditions such as Pd/C ' and H2 or SnCl2, thiol, or zinc in acetic acid to form the amine 4-scheme-4.
- the amine can be coupled with the commericially available isocyanate.
- the desired isocyanates can be made by condensing the amine with triphosgene in the presence of base (such as potassium carbonate) or by reacting the carboxylic acid with diphenyl phosphorazide in the presence of a base (such as triethyl amine).
- Another aspect of the present invention is the novel process of making a compound of Formula (I) which process comprises condensing an isocyanate derivative of the formula
- Another aspect of the present invention is the process of making a compound of Formula (II) which process comprises condensing an isocyanate derivative of the formula wherein R ⁇ , R 4, v and Z are as defined for Formula (II); with a compound of the Formula (Ha) :
- Another aspect of the present invention is the process of making a compound of Formula (III) which process comprises condensing an isocyanate derivative of the formula
- Rl is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted Ci-io alkyl, Ci-io alkyl, C2-10 alkenyl, Ci-io alkoxy, halosubstituted Ci-io alkoxy, (CRgRg)q S(O) t R4, hydroxy, hydroxy Cj-4alkyl, aryl, aryl Ci-4 alkyl, aryloxy, aryl Ci-4 alkyloxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic Ci-4alkyl, heteroaryl Ci-4 alkyloxy, aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl, (CRgRg)qNR4R5, C2-10 alkenyl C(O)NR4R5, (CRgRg)q C(O)NR 4 R5, (CR 8 R 8 )q C(O)NR 4 Rl
- NR4C(O)Rn (CR 8 R 8 )qC(NR 4 )NR 4 R5, (CR 8 Rg)q NR 4 C(NR 5 )Rn, (CR 8 R 8 )q NHS(O) Ri7, or (CR 8 Rg)q S(O)2NR4R 5 ; and wherein the aryl, heteroaryl, and heterocyclic containing moieties may all be optionally substituted;
- m is an integer having a value of 1 to 3; q is 0, or an integer having a value of 1 to 10;
- s is an integer having a value of 1 to 3;
- t is 0, or an integer having a value of 1 or 2;
- R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci-4alkyl, heterocyclic, heterocyclic C ⁇ _4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S;
- R 8 is hydrogen or Cj-4 alkyl;
- RlO is C 1-10 alkyl C(O)2R 8 ;
- Rl l i hydrogen, Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 _4alkyl;
- Rl2 is hydrogen, Ci-io alkyl, optionally substituted aryl or optionally substituted arylalkyl;
- Rl7 is Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Cj-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ⁇ _4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC 1 -4alkyl.
- Yet another aspect of the present invention is the novel intermediate compounds of Formula (II) and (III) which are the pyridine isomers of Formula (I) as described above.
- Yet another aspect of the present invention is the novel process of making a compound of Formula (la) which process comprises cyclizing a compound of the formula: under standard conditions and then reducing under standard conditions to yield a compound of Formula (la).
- Yet another aspect of the present invention is the novel process of making a compound of Formula (Ila) which process comprises cyclizing a compound of the formula:
- Yet another aspect of the present invention is the novel process of making a compound of Formula (Ilia) which process comprises cyclizing a compound of the formula:
- 2-amino-3,5-dibromo-4-methylpyridine (8g, 30.0mmol) was cooled to 10° C, followed by the addition of concentrated sulfuric acid(l ⁇ ml). The mixture was stirred, maintaining the temperature at 10° C for 2hrs, with the addition of a mixture of 30% hydrogen peroxide in 30% fuming sulfuric acid(25ml/50ml). The mixture was allowed to warm to room temperature and stirred for an additional 48 hrs. The reaction was then added to 300ml of water with cooling and made very slightly basic with dropwise addition of 505 NaOH solution while the temperature was maintained at 20-25o C. The product was extracted using ether(4x 150ml) and dried with
- N-[pyrsulfonamide]-N'-[2-bromophenyl] urea is prepared from 2-amino-5- bromo-4-cyclicsulfonamide pyridine (wt, mol) according to the procedure in General
- Method B The product is purified by chromatography of the resulting solid on silica gel (EtOAc/ hexane(2equiv./3equiv.)). (yield) ⁇ NMR (CD 3 SO 2 CD 3 ): ⁇ ( proton nmr).
- the compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines which bind to the IL-8 or ⁇ receptor, also referred to as the type I or type II receptor.
- the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 ⁇ or ⁇ receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
- the chemokines are IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78.
- the compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state.
- Abnormal levels of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 for instance in the context of the present invention constitute: (i) levels of free IL-8 greater than or equal to 1 picogram per mL; (ii) any cell associated IL-8, GRO ⁇ , GRO ⁇ GRO ⁇ , NAP-2 or ENA-78 above normal physiological levels; or (iii) the presence of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 above basal levels in cells or tissues in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 respectively, is produced.
- Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, Alzheimer's disease, allograft rejections, malaria, restinosis, angiogenesis or undesired hematopoietic stem cells release, rhinovirus infections, and various bone resorption indications.
- the ⁇ -chemokines but particularly, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78, working through the IL- 8 type I or II receptor can promote the neovascularization of tumors by promoting the directional growth of endothelial cells. Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration.
- the present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I).
- CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area.
- Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
- the role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.
- TNF- ⁇ is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression.
- Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al., Stoke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.
- the compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation.
- the discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein.
- the compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.
- IL-8 mediated disease or disease state refers to any and all disease states in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 plays a role, either by production of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 themselves, or by IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , NAP-2 or ENA-78 causing another monokine to be released, such as but not limited to IL- 1 , IL-6 or TNF.
- a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
- chemokine mediated disease or disease state refers to any and all disease states in which a chemokine which binds to an IL-8 ⁇ or ⁇ receptor plays a role, such as but not limited to IL-8, GRO- ⁇ , GRO- ⁇ , GRO ⁇ , NAP- 2 or ENA-78.
- a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.
- cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
- a cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them.
- a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte.
- Lymphokines are generally referred to as being produced by lymphocyte cells.
- cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor beta (TNF- ⁇ ).
- chemokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term “cytokine” above.
- a chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells.
- chemokines include, but are not limited to, IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, IP- 10, MlP-l ⁇ , MlP- ⁇ , PF4, and MCP 1, 2, and 3.
- a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
- This invention also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
- Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation.
- the compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures.
- the compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
- the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the pharmaceutical carrier employed may be, for example, either a solid or liquid.
- solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- liquid carriers are syrup, peanut oil, olive oil, water and the like.
- the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
- the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg.
- the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
- Compounds of Formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
- systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
- Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
- the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the Formulation.
- Lotions according to the present invention include those suitable for application to the skin or eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
- Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
- Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
- the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel.
- the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
- the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C. for half an hour.
- the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
- bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
- Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
- Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration.
- Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
- the daily oral dosage regimen will preferably be from about 0.01 to about 80 mg/kg of total body weight.
- the daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight.
- the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
- the daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
- the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- IL-8, and Gro- ⁇ chemokine inhibitory effects of compounds of the present invention are determined by the following in vitro assay: Receptor Binding Assays:
- [125 ⁇ ] iL_g (human recombi ⁇ ant) is obtained from Amersham Corp., Arlington Heights, IL, with specific activity 2000 Ci/mmol. Gro- ⁇ is obtained from NEN- New England Nuclear. All other chemicals are of analytical grade. High levels of recombinant human IL-8 type ⁇ and ⁇ receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, et al., Science, 1991, 253, 1278). The Chinese hamster ovary membranes were homogenized according to a previously described protocol (Haour, et al., J Biol Chem., 249 pp 2195-2205 (1974)).
- homogenization buffer is changed to lOmM Tris-HCL, ImM MgS04, 0.5mM EDTA (ethylene-diaminetetra- acetic acid), lmMPMSF ( ⁇ -toluenesulphonyl fluoride), 0.5 mg/L Leupeptin, pH 7.5.
- Membrane protein concentration is determined using Pierce Co. micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format.
- Each reaction mixture contains 25 jL_g (0.25 nM) or 125 ⁇ Gro- ⁇ and 0.5 ⁇ g/mL of IL-8R ⁇ or 1.0 ⁇ g/mL of IL-8R ⁇ membranes in 20 mM Bis- Trispropane and 0.4 mM Tris HC1 buffers, pH 8.0, containing 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl and 0.03% CHAPS.
- drug or compound of interest is added which has been pre-dissolved in DMSO so as to reach a final concentration of between 0.0 InM and 100 uM.
- the assay is initiated by addition of 25 ⁇ _iL- _ After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1 % polyethylenimine/ 0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl, 1 mM MgSO4,
- the filter is then dried and counted on the Betaplate liquid scintillation counter.
- the recombinant IL-8 R ⁇ , or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 R ⁇ , or Type II, receptor is referred to as the permissive receptor.
- the in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol. I, Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in its entirety.
- Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1, whose disclosure is incorporated herein by reference in its entirety.
- the chemoattractants IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM. The two chambers are separated by a 5um polycarbonate filter.
- the compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils.
- Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1.
- PMNs 0.88 x 10 6 cells suspended in Ringer's Solution (NaCl 1 18, KC1 4.56, NaHCO3 25, KH2PO4 1.03, Glucose 1 1.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 ul.
- test compound 0.001 - 1000 nM
- Cytochalasin B in a volume of 50 ul (20ug/ml)
- Ringers buffer in a volume of 50 ul.
- These cells are allowed to warm (37 °C, 5% CO2, 95% RH) for 5 min. before IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2 at a final concentration of 0.01 - 1000 nM was added.
- the reaction is allowed to proceed for 45 min. before the 96 well plate is centrifuged (800 xg 5 min.) and 100 ul of the supernatant removed.
- This supernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala- Ala-Pro- Val- AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline.
- the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 min. intervals according to the method of Nakajima et al J. Biol. Chem. 254 4027 (1979).
- the amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.
- the present assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats.
- TBI experimentally induced lateral fluid- percussion traumatic brain injury
- LC left (injured) parietal cortex
- RC contralateral right cortex
- LA cortex adjacent to injured parietal cortex
- RA right cortex
- RH right hippocampus
- TNF- ⁇ mRNA expression is observed in LH (104 ⁇ 17% of positive control, p ⁇ 0.05 compared with sham), LC (105 ⁇ 21%, p ⁇ 0.05) and LA (69 ⁇ 8%, p ⁇ 0.01) in the traumatized hemisphere 1 hr. following injury.
- An increased TNF- ⁇ mRNA expression is also observed in LH (46 ⁇ 8%, p ⁇ 0.05), LC (30 ⁇ 3%, p ⁇ 0.01) and LA (32 ⁇ 3%, p ⁇ 0.01) at 6 hr. which resolves by 24 hr. following injury.
- TNF- ⁇ mRNA In the contralateral hemisphere, expression of TNF- ⁇ mRNA is increased in RH (46 ⁇ 2%, p ⁇ 0.01), RC (4 ⁇ 3%) and RA (22 ⁇ 8%) at 1 hr. and in RH (28 ⁇ 11%), RC (7 ⁇ 5%) and RA (26 ⁇ 6%, p ⁇ 0.05) at 6 hr. but not at 24 hr. following injury. In sham (surgery without injury) or naive animals, no consistent changes in expression of TNF- ⁇ mRNA are observed in any of the 6 brain areas in either hemisphere at any times.
- TNF- ⁇ is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- ⁇ plays an important role in both the acute and regenerative response to CNS trauma.
- NGF nerve growth factor
- This assay characterizes the regional expression of interleukin-l ⁇ (IL-1B) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats.
- TBI lateral fluid-percussion traumatic brain injury
- LC left (injured) parietal cortex
- RC contralateral right cortex
- LA cortex adjacent to injured parietal cortex
- RA right cortex
- LH left hippocampus
- RH right hippocampus
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/806,119 US6440993B1 (en) | 1999-10-12 | 1999-10-12 | IL-8 receptor antagonists |
EP99956537A EP1121360A4 (en) | 1998-10-13 | 1999-10-12 | Il-8 receptor antagonists |
JP2000575869A JP2002527441A (en) | 1998-10-13 | 1999-10-12 | IL-8 receptor antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10401698P | 1998-10-13 | 1998-10-13 | |
US60/104,016 | 1998-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000021963A1 true WO2000021963A1 (en) | 2000-04-20 |
Family
ID=22298254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/023776 WO2000021963A1 (en) | 1998-10-13 | 1999-10-12 | Il-8 receptor antagonists |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1121360A4 (en) |
JP (1) | JP2002527441A (en) |
WO (1) | WO2000021963A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114949A (en) * | 1989-11-20 | 1992-05-19 | Rhone-Poulenc Sante | Heterocyclic derivatives, their preparation and medicinal products containing them |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000057137A (en) * | 1996-11-19 | 2000-09-15 | 스티븐 엠. 오드레 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
AR008331A1 (en) * | 1997-01-23 | 1999-12-29 | Smithkline Beecham Corp | ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
ES2224365T3 (en) * | 1997-02-12 | 2005-03-01 | Smithkline Beecham Corporation | IL-8 RECEIVER ANTAGONISTS. |
-
1999
- 1999-10-12 JP JP2000575869A patent/JP2002527441A/en not_active Withdrawn
- 1999-10-12 WO PCT/US1999/023776 patent/WO2000021963A1/en not_active Application Discontinuation
- 1999-10-12 EP EP99956537A patent/EP1121360A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114949A (en) * | 1989-11-20 | 1992-05-19 | Rhone-Poulenc Sante | Heterocyclic derivatives, their preparation and medicinal products containing them |
Non-Patent Citations (1)
Title |
---|
See also references of EP1121360A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1121360A4 (en) | 2002-01-23 |
EP1121360A1 (en) | 2001-08-08 |
JP2002527441A (en) | 2002-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6271261B1 (en) | IL-8 receptor antagonists | |
US6297265B2 (en) | Benzoisothiazole-substituted compounds useful as IL-8 receptor antagonists | |
US6218539B1 (en) | IL-8 receptor antagonists | |
EP1005341B1 (en) | Il-8 receptor antagonists | |
US6316478B1 (en) | IL-8 receptor antagonists | |
EP1274415A2 (en) | Il-8 receptor antagonists | |
EP0971908B1 (en) | Il-8 receptor antagonists | |
WO1998034929A9 (en) | Il-8 receptor antagonists | |
US6221889B1 (en) | IL-8 receptor antagonists | |
US6653310B2 (en) | IL-8 receptor antagonists | |
US6436927B1 (en) | IL-8 receptor antagonists | |
US6440993B1 (en) | IL-8 receptor antagonists | |
EP1274413A2 (en) | Il-8 receptor antagonists | |
WO1999036069A1 (en) | Il-8 receptor antagonists | |
EP0915653A1 (en) | Il-8 receptor antagonists | |
EP1121360A1 (en) | Il-8 receptor antagonists | |
EP1098884A1 (en) | Il-8 receptor antagonists | |
WO2001007045A1 (en) | Il-8 receptor antagonists | |
WO2000069435A1 (en) | Il-8 receptor antagonists | |
WO1999065310A1 (en) | Il-8 receptor antagonists | |
WO2000076508A1 (en) | Il-8 receptor antagonists | |
NZ521057A (en) | IL-8 receptor antagonists | |
MXPA01000822A (en) | Il-8 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09806119 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 575869 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999956537 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999956537 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999956537 Country of ref document: EP |